This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Race investor briefing & updated presentation
Race Oncology Limited (ASX: RAC) (Race) is pleased to release an updated
investor presentation and invite investors to join a special online investor briefing.
Updated Presentation
- An update on the Company’s Three Pillar strategy and recent related highlights
- Updates to the Board and extended team slides
- Additional information on the FTO pathway (Pillar 1) for Bisantrene, including relevant comparators
- Coming milestones and the expected activity timeline for Bisantrene’s continued development
Investor Briefing Invitation
Investors are invited to attend a special briefing session where Managing Director and CEO, Phillip Lynch and CSO and Executive Director, Dr Daniel Tillett will discuss progress on the Company’s Three Pillar strategy, as well as the recently announced capital raise and Bonus Options Issue. Details as follows:
When
Thursday 13 May from 10:30am AEST
Register
https://us02web.zoom.us/webinar/register/WN_04Io2ZClRrSvGsfoZGlW2Q
Q+A
Investors will be invited to ask questions during the session.